BioAtla
Developer of conditionally active biologics engineered to change antigen-binding activity in response to defined physiological conditions (for example tumor microenvironment characteristics). Applies conditional-activation approaches across antibody formats (naked antibodies, ADCs, bispecifics, CAR-T) and advances programs through preclinical development and early-phase clinical trials, while maintaining patent coverage and regional partnerships.
Industries
Nr. of Employees
medium (51-250)
Patents
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US-12649793-B2
View DetailsConditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
US-12427347-B2
View Details
Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof
US-12649793-B2
View DetailsConditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereof
US-12427347-B2
View DetailsProducts
AXL-targeting conditionally active ADC (clinical-stage)
A conditionally active antibody-drug conjugate targeting the receptor tyrosine kinase AXL, evaluated in clinical studies for sarcoma, non-small cell lung cancer and ovarian cancer as monotherapy and in combination with PD-1 inhibitors.
ROR2-targeting conditionally active ADC (clinical-stage)
A conditionally active ADC targeting ROR2, evaluated in clinical trials for melanoma, NSCLC, head and neck, and ovarian cancers with selective tumor binding to reduce off-tumor toxicity.
Conditionally active anti–CTLA-4 checkpoint antibody (clinical-stage)
A conditionally active immune checkpoint antibody engineered to localize immune activation to the tumor microenvironment to reduce systemic immune-mediated toxicity.
Conditionally active bispecific EpCAM × CD3 T-cell engager (clinical-stage)
A bispecific T-cell engager that uses conditional antigen-binding domains to direct T cells to EpCAM-expressing adenocarcinomas while limiting systemic T-cell activation.
Next-generation Nectin-4-targeting conditionally active ADC (preclinical/clinical development)
A conditionally active ADC combining tumor-selective antibodies with a glycosidase-cleavable linker to maximize intratumoral payload release and improve therapeutic index against Nectin-4–expressing tumors.
Mecbotamab Vedotin
A CAB ADC targeting AXL featuring a Val/Cit protease cleavable linker and MMAE payload.
AXL-targeting conditionally active ADC (clinical-stage)
A conditionally active antibody-drug conjugate targeting the receptor tyrosine kinase AXL, evaluated in clinical studies for sarcoma, non-small cell lung cancer and ovarian cancer as monotherapy and in combination with PD-1 inhibitors.
ROR2-targeting conditionally active ADC (clinical-stage)
A conditionally active ADC targeting ROR2, evaluated in clinical trials for melanoma, NSCLC, head and neck, and ovarian cancers with selective tumor binding to reduce off-tumor toxicity.
Conditionally active anti–CTLA-4 checkpoint antibody (clinical-stage)
A conditionally active immune checkpoint antibody engineered to localize immune activation to the tumor microenvironment to reduce systemic immune-mediated toxicity.
Conditionally active bispecific EpCAM × CD3 T-cell engager (clinical-stage)
A bispecific T-cell engager that uses conditional antigen-binding domains to direct T cells to EpCAM-expressing adenocarcinomas while limiting systemic T-cell activation.
Next-generation Nectin-4-targeting conditionally active ADC (preclinical/clinical development)
A conditionally active ADC combining tumor-selective antibodies with a glycosidase-cleavable linker to maximize intratumoral payload release and improve therapeutic index against Nectin-4–expressing tumors.
Mecbotamab Vedotin
A CAB ADC targeting AXL featuring a Val/Cit protease cleavable linker and MMAE payload.
Services
Research and development services using conditional-activation approaches (small-molecule/pH-sensitive switches and conditional antibody engineering) to generate therapeutics for oncology and age-related indications.
Discovery and evolution of protein candidates directly in intended manufacturing hosts and provision of host-vector optimization to reduce downstream process development and improve expression yields.
Research and development services using conditional-activation approaches (small-molecule/pH-sensitive switches and conditional antibody engineering) to generate therapeutics for oncology and age-related indications.
Discovery and evolution of protein candidates directly in intended manufacturing hosts and provision of host-vector optimization to reduce downstream process development and improve expression yields.
Expertise Areas
- Conditionally active biologics
- Antibody-drug conjugate design and linker chemistry
- Bispecific antibody and T-cell engager engineering
- Preclinical in vivo pharmacology and safety assessment
Key Technologies
- Protein-associated chemical switch mechanisms
- Conditional-activation antibody engineering
- Glycosidase-cleavable ADC linker chemistry
- Bispecific T-cell engager constructs
News & Updates
Clinical presentation reporting median overall survival among treatment-refractory sarcoma patients treated with an AXL-targeting ADC.
Presentation of first-in-human Phase 1 data for a dual-conditionally active EpCAM × CD3 bispecific T-cell engager in patients with treatment-refractory metastatic adenocarcinoma.
Phase 2 clinical trial poster reporting activity of a conditionally binding ROR2-targeting ADC in head and neck squamous cell carcinoma.
Preclinical research report describing development, characterization and preclinical performance of a conditionally active AXL-targeting ADC.
Clinical presentation reporting median overall survival among treatment-refractory sarcoma patients treated with an AXL-targeting ADC.
Presentation of first-in-human Phase 1 data for a dual-conditionally active EpCAM × CD3 bispecific T-cell engager in patients with treatment-refractory metastatic adenocarcinoma.
Phase 2 clinical trial poster reporting activity of a conditionally binding ROR2-targeting ADC in head and neck squamous cell carcinoma.
Preclinical research report describing development, characterization and preclinical performance of a conditionally active AXL-targeting ADC.